David R. Fogelman

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

45h-index6.8kcitations232works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic and Hepatic Oncology Research(92), Colorectal Cancer Treatments and Studies(86), Cancer Genomics and Diagnostics(78), Genetic factors in colorectal cancer(32), Neuroendocrine Tumor Research Advances(26)

Publications231 total

Phase I Trial of Binimetinib Plus Hydroxychloroquine in Patients with Previously Treated Metastatic Pancreatic Cancer
The Oncologist·2026Open Access
KEYSTEP-008: Pembrolizumab (pembro)-based combinations for microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).
Journal of Clinical Oncology·2026
Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of pembrolizumab (pembro) versus chemotherapy (chemo) in microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC) in the KEYNOTE-177 trial.
Journal of Clinical Oncology·2025
Prevalence of PD-L1 expression and <i>RAS</i> mutations and association with overall survival in metastatic colorectal cancer patients.
Journal of Clinical Oncology·2025
A phase I trial of binimetinib plus hydroxychloroquine inpatients with previously treated metastatic pancreatic cancer.
Journal of Clinical Oncology·2025
Use of Real-World Data to Support Economic Evaluations of Tumor-Agnostic Therapies: Challenges Remain
Value in Health·2025
Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: The phase 3, randomized KEYFORM-007 study.
Journal of Clinical Oncology·2025· 4 cited
KEYSTEP-008: Phase II Trial of Pembrolizumab-Based Combination in MSI-H/dMMR Metastatic Colorectal Cancer
Future Oncology·2023· 12 citedOpen Access
Supplementary Figure 1 from Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600E&lt;/sup&gt; Mutation
2023Open Access
Data from Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600E&lt;/sup&gt; Mutation
2023Open Access
Supplementary Table 1 from Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600E&lt;/sup&gt; Mutation
2023Open Access
Supplementary Figure 1 from Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600E&lt;/sup&gt; Mutation
2023Open Access
Data from Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600E&lt;/sup&gt; Mutation
2023Open Access
Supplementary Figure 3 from Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600E&lt;/sup&gt; Mutation
2023Open Access
Supplementary Figure 4 from Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600E&lt;/sup&gt; Mutation
2023Open Access
Supplementary Table 1 from Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600E&lt;/sup&gt; Mutation
2023Open Access
Supplementary Figure 3 from Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600E&lt;/sup&gt; Mutation
2023Open Access
Supplementary Figure 4 from Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600E&lt;/sup&gt; Mutation
2023Open Access
Supplementary Figure 2 from Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600E&lt;/sup&gt; Mutation
2023Open Access
Supplementary Figure 2 from Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600E&lt;/sup&gt; Mutation
2023Open Access
page 1 of 12Next →

Frequent Co-authors

Robert A. Wolff(27), Michael J. Overman(23), Matthew H. G. Katz(18), Milind Javle(17), Gauri R. Varadhachary(15), Scott Kopetz(14), Jeffrey E. Lee(14), Rachna T. Shroff(11), Jason B. Fleming(11), Cathy Eng(10), Michael P. Kim(10), Huamin Wang(8), Bryan K. Kee(8), Ching‐Wei D. Tzeng(8), Arvind Dasari(8), Jean‐Nicolas Vauthey(7), Eugene J. Koay(7), Van K. Morris(6), Laura Prakash(6), Maria Q. B. Petzel(6)